



June 25, 2015

## **Fluidigm Introduces Advanced Mass Cytometry System**

### **Along with sample barcoding for markedly improved discovery workflows**

**Fluidigm's New Helios Platform Combines Ease-of-Use Enhancements with Multi-Modal Capabilities for High-Resolution, High-Content Single-Cell Biology**

SOUTH SAN FRANCISCO, Calif., June 25, 2015 – Fluidigm Corporation (NASDAQ:FLDM) today introduced Helios™, a CyTOF® platform that enables system-level biology at single-cell resolution, on an accessible, expandable system designed for breakthrough discovery. Mass cytometry has catalyzed the revolution of single-cell proteomics, enabling the most comprehensive understanding of cell phenotypes, signaling pathways and function. Helios dawns as the most advanced tool for cellular exploration with streamlined workflows and multi-modal capabilities for advancing single-cell biology.

The Helios platform delivers an extensive list of features and advances to the core CyTOF technology, all intended to bring enhanced performance and convenience of operation. This includes a significantly more intuitive and easy-to-use software interface with real-time data display, normalization and control. Helios also provides improved sensitivity to detect and resolve lower abundance targets and an expanded mass range of 135 discrete channels with virtually no signal overlap or background noise compared to conventional techniques. This enables more comprehensive and straightforward panel designs and higher quality data sets. A synchronized suite of upgrades to the sample introduction assembly and procedure triples the rate of data acquisition, or system throughput, with a considerable increase in cell transmission efficiency and consistency.

Fluidigm also announced proteomics sample barcoding, which enables Helios and all other CyTOF customers to take advantage of multiplexing in their experimental design. Fluidigm's new barcoding reagent kit accommodates the unique barcoding of up to 20 samples such that they can be combined, stained and acquired as one multiplexed sample. Multiplexing improves data quality as samples are prepared, processed and acquired under a common protocol, thereby eliminating any technical variation from sample preparation through data collection. It substantially increases throughput by reducing staining protocol and instrument collection time. Barcoding is indispensable for any experiment where unraveling of biological complexity requires multiple samples, time points and assay conditions.

"The Helios platform and sample barcoding deliver significant improvements to performance, ease-of-use, and data quality to our customers, providing more parametric information from a single sample than any other cellular analysis system in the marketplace," said Gajus Worthington, Fluidigm President and Chief Executive Officer. "We also plan to enable single-cell RNA profiling and high-dimensional in-situ imaging on the Helios system in the near future," Worthington noted.

Fluidigm will begin shipments of Helios systems in the third quarter of 2015.

### **Fluidigm at CYTO 2015**

Fluidigm is unveiling the Helios platform with sample barcoding at CYTO 2015, the 30th Congress of the International Society for Advancement of Cytometry being held this week in Glasgow, United Kingdom with product demonstrations, seminars and workflow consultations available to all attendees. In addition, Fluidigm will be hosting a CyTOF User Group meeting and reception that will feature presentations by Fluidigm customers from around the world.

### **Use of Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Fluidigm's new products, and Fluidigm's plans, objectives, expectations and/or strategies relating to such new products. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including challenges inherent in developing, manufacturing, launching, marketing, and selling new products; Fluidigm's sales, marketing, manufacturing, and distribution capabilities; and interruptions or delays in the supply of components or materials for, or manufacturing of, its products.

Information on these and additional risks affecting Fluidigm's business and operating results are contained in its filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Fluidigm disclaims any obligation to update these statements except as may be required by law.

## About Fluidigm

Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for growth markets such as single-cell biology and production genomics. We sell to leading academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multi-parameter mass cytometry technology, and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs, while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

We use our website ([www.fluidigm.com](http://www.fluidigm.com)), corporate Twitter account ([@Fluidigm](https://twitter.com/Fluidigm)), Facebook page (<https://www.facebook.com/Fluidigm>), and LinkedIn page (<https://www.linkedin.com/company/fluidigm-corporation>) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.

For more information, please visit: [www.fluidigm.com](http://www.fluidigm.com).

Fluidigm, the Fluidigm logo, CyTOF, and Helios are trademarks or registered trademarks of Fluidigm Corporation.

## Contact

Michaeline Bunting  
Senior Director, Marketing  
Fluidigm Corporation  
650 737 4190 (office)  
[michaeline.bunting@fluidigm.com](mailto:michaeline.bunting@fluidigm.com)

Robert Ellis  
Director, Product Management, Proteomics  
Fluidigm Corporation  
905 943 0128 (office)  
416 707 0837 (mobile)  
[robert.ellis@fluidigm.com](mailto:robert.ellis@fluidigm.com)

Kevin Farrell  
Vice President, Commercial Support Operation  
Fluidigm Corporation  
650- 266 6027 (office)  
650 823 4670 (mobile)  
[kevin.farrell@fluidigm.com](mailto:kevin.farrell@fluidigm.com)